Operating profit margin has declined from 34.15% to 29.76%, leading to 6.86% decline in operating profit to Rs 189.37 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 14.65% to 13.62%.   Purchase of finished goods cost rose from 17.67% to 29.24%.   Employee cost decreased from 15.21% to 15.14%.   Other expenses fell from 16.60% to 15.27%.   

Other income up 23.70% to Rs 15.03 crore.  PBIDT fell 5.14% to Rs 204.4 crore.  Provision for interest fell 53.08% to Rs 2.21 crore.  Loan funds rose to Rs 47.54 crore as of 30 September 2021 from Rs 2.50 crore as of 30 September 2020.  Inventories rose to Rs 449.61 crore as of 30 September 2021 from Rs 415.14 crore as of 30 September 2020.  Sundry debtors were higher at Rs 172.32 crore as of 30 September 2021 compared to Rs 157.54 crore as of 30 September 2020.  Cash and bank balance rose to Rs 1,515.45 crore as of 30 September 2021 from Rs 994.09 crore as of 30 September 2020.  

PBDT fell 4.07% to Rs 202.19 crore.  Provision for depreciation down 1.80% to Rs 27.23 crore.  Fixed assets declined from Rs 239.69 crore as of 30 September 2020 to Rs 203.21 crore as of 30 September 2021.  Intangible assets declined from Rs 701.45 crore to Rs 647.20 crore.  

Profit before tax down 4.41% to Rs 174.96 crore.  Provision for tax was expense of Rs 32.01 crore, compared to Rs 51.66 crore.  Effective tax rate was 18.30% compared to 28.22%.

Profit after tax rose 8.81% to Rs 142.95 crore.  

Equity capital stood at Rs 45.75 crore as of 30 September 2021 to Rs 45.75 crore as of 30 September 2020.  Per share face Value remained same at Rs 10.00.  

Promoters' stake was 63.92% as of 30 September 2021 ,compared to 63.92% as of 30 September 2020 .  

  
For year-to-date (YTD) results analysis

Net sales (including other operating income) of Pfizer has increased 24.78% to Rs 1,385.43 crore.  

Operating profit margin has declined from 35.09% to 34.29%, leading to 21.95% rise in operating profit to Rs 475.11 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 14.22% to 13.26%.   Purchase of finished goods cost rose from 20.20% to 25.66%.   Employee cost decreased from 15.66% to 14.00%.   Other expenses fell from 14.48% to 14.08%.   

Other income fell 7.09% to Rs 27.27 crore.  PBIDT rose 19.91% to Rs 502.38 crore.  Provision for interest fell 42.23% to Rs 4.46 crore.  Loan funds rose to Rs 47.54 crore as of 30 September 2021 from Rs 2.50 crore as of 30 September 2020.  Inventories rose to Rs 449.61 crore as of 30 September 2021 from Rs 415.14 crore as of 30 September 2020.  Sundry debtors were higher at Rs 172.32 crore as of 30 September 2021 compared to Rs 157.54 crore as of 30 September 2020.  Cash and bank balance rose to Rs 1,515.45 crore as of 30 September 2021 from Rs 994.09 crore as of 30 September 2020.  

PBDT rose 21.08% to Rs 497.92 crore.  Provision for depreciation down 1.17% to Rs 54.23 crore.  Fixed assets declined from Rs 239.69 crore as of 30 September 2020 to Rs 203.21 crore as of 30 September 2021.  Intangible assets declined from Rs 701.45 crore to Rs 647.20 crore.  

Profit before tax grew 24.50% to Rs 443.69 crore.  Provision for tax was expense of Rs 100.83 crore, compared to Rs 100.55 crore.  Effective tax rate was 22.73% compared to 28.22%.

Profit after tax rose 34.02% to Rs 342.86 crore.  

Equity capital stood at Rs 45.75 crore as of 30 September 2021 to Rs 45.75 crore as of 30 September 2020.  Per share face Value remained same at Rs 10.00.  

Promoters' stake was 63.92% as of 30 September 2021 ,compared to 63.92% as of 30 September 2020 .  

Full year results analysis

Net sales (including other operating income) of Pfizer has increased 4.04% to Rs 2,238.55 crore.  

Operating profit margin has jumped from 26.61% to 31.81%, leading to 24.37% rise in operating profit to Rs 712.12 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.78% to 15.05%.   Purchase of finished goods cost fell from 22.11% to 20.17%.   Employee cost decreased from 16.66% to 16.23%.   Other expenses fell from 19.29% to 16.53%.   

Other income fell 55.92% to Rs 81.12 crore.  PBIDT rose 4.85% to Rs 793.24 crore.  Provision for interest up 39.26% to Rs 15.11 crore.  Loan funds rose to Rs 63.23 crore as of 31 March 2021 from Rs 2.50 crore as of 31 March 2020.  Inventories rose to Rs 435.05 crore as of 31 March 2021 from Rs 430.59 crore as of 31 March 2020.  Sundry debtors were lower at Rs 129.69 crore as of 31 March 2021 compared to Rs 172.03 crore as of 31 March 2020.  Cash and bank balance declined from Rs 2,219.87 crore as of 31 March 2020 to Rs 1,115.10 crore as of 31 March 2021.  

PBDT rose 4.34% to Rs 778.13 crore.  Provision for depreciation rose 5.98% to Rs 109.41 crore.  Fixed assets declined from Rs 246.23 crore as of 31 March 2020 to Rs 224.70 crore as of 31 March 2021.  Intangible assets declined from Rs 727.39 crore to Rs 672.36 crore.  

Profit before tax grew 4.08% to Rs 668.72 crore.  Provision for tax was expense of Rs 171.11 crore, compared to Rs 133.36 crore.  Effective tax rate was 25.59% compared to 20.76%.

Profit after tax fell 2.26% to Rs 497.61 crore.  

Equity capital stood at Rs 45.75 crore as of 30 September 2021 to Rs 45.75 crore as of 30 September 2020.  Per share face Value remained same at Rs 10.00.  

Promoters' stake was 63.92% as of 31 March 2021 ,compared to 63.92% as of 31 March 2020 .  

Cash flow from operating activities increased to Rs 427.33 crore for year ended March 2021 from Rs 323.18 crore for year ended March 2020.  Cash flow used in acquiring fixed assets during the year ended March 2021 stood at Rs 17.70 crore, compared to Rs 16.88 crore during the year ended March 2020.